drugset
Drugs / HB0052
last change Nov 2025 re-read 3 minutes ago

HB0052

Other / unclassified

Developed for
cancer
Investigated by
Huazhong University of Science and Technology · Hunan Cancer Hospital · Peking University Cancer Hospital & Institute · Shandong Cancer Hospital and Institute · Shanghai Huaota Biopharmaceutical Co., Ltd. · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
+2 more · The Second Affiliated Hospital of Harbin Medical University · Zhejiang Cancer Hospital

Trials 1

today NCT06992687 · Ph 1/2
20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06992687 Sep 2024 → Sep 2025 overdue cancer Shanghai Huaota Biopharmaceutical Co., Ltd. Enrolling by invitation No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HB0052 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06992687 ↗
Modality Other / unclassified “An antibody- drug conjugate (ADC)” NCT06992687 ↗
Route Intravenous “IV every 3 weeks (q3w)” NCT06992687 ↗